114 related articles for article (PubMed ID: 32558229)
21. Irreversible cytotoxic effect of a novel lowly immunosuppressive antitumor fluorouridine derivative, UK-21.
Mori H; Nakayama K; Ishida R; Ito S; Nagai H; Koda A
Anticancer Drugs; 1997 Jun; 8(5):482-8. PubMed ID: 9215612
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer.
Nam HJ; Ching KA; Kan J; Kim HP; Han SW; Im SA; Kim TY; Christensen JG; Oh DY; Bang YJ
Mol Cancer Ther; 2012 Feb; 11(2):439-51. PubMed ID: 22135232
[TBL] [Abstract][Full Text] [Related]
23. The effect of direct translocation across endosomes on the cytotoxicity of the recombinant protein e23sFv-Fdt-casp6 to HER2 positive gastric cancer cells.
Ren JL; Meng YL; Hu B; Jia LT; Zhang R; Xu YM; Xie QS; Zhang YQ; Jin BQ; Chen SY; Wang T; Yang AG
Biomaterials; 2011 Oct; 32(30):7641-50. PubMed ID: 21767874
[TBL] [Abstract][Full Text] [Related]
24. Temporal Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors.
Pereira PMR; Mandleywala K; Ragupathi A; Carter LM; Goos JACM; Janjigian YY; Lewis JS
J Nucl Med; 2019 Nov; 60(11):1569-1578. PubMed ID: 31171598
[TBL] [Abstract][Full Text] [Related]
25. Antiproliferative effect of immunoliposomes containing 5-fluorodeoxyuridine-dipalmitate on colon cancer cells.
Koning GA; Gorter A; Scherphof GL; Kamps JA
Br J Cancer; 1999 Aug; 80(11):1718-25. PubMed ID: 10468287
[TBL] [Abstract][Full Text] [Related]
26. Rate-limiting steps in the interactions of fluoropyrimidines and methotrexate.
Bowen D; Bailey BD; Guernsey LA
Eur J Cancer Clin Oncol; 1984 May; 20(5):651-7. PubMed ID: 6234172
[TBL] [Abstract][Full Text] [Related]
27. Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule.
Friedman M; Lindström S; Ekerljung L; Andersson-Svahn H; Carlsson J; Brismar H; Gedda L; Frejd FY; Ståhl S
Biotechnol Appl Biochem; 2009 Aug; 54(2):121-31. PubMed ID: 19492986
[TBL] [Abstract][Full Text] [Related]
28. A novel dual EGFR/HER2 inhibitor KU004 induces cell cycle arrest and apoptosis in HER2-overexpressing cancer cells.
Tian C; Ding P; Yuan Z; Li H; Zhao Y; Sun L; Guo Q; Wang Z; Sun L; Zhang L; Jiang Z
Apoptosis; 2015 Dec; 20(12):1599-612. PubMed ID: 26437915
[TBL] [Abstract][Full Text] [Related]
29. Use of 5-fluorodeoxyuridine (FUDR) as an adjuvant to the surgical management of carcinoma of the stomach.
Serlin O; Wolkoff JS; Amadeo JM; Keehn RJ
Cancer; 1969 Aug; 24(2):223-8. PubMed ID: 4240353
[No Abstract] [Full Text] [Related]
30. HER2 Targeted Breast Cancer Therapy with Switchable "Off/On" Multifunctional "Smart" Magnetic Polymer Core-Shell Nanocomposites.
Vivek R; Thangam R; Kumar SR; Rejeeth C; Kumar GS; Sivasubramanian S; Vincent S; Gopi D; Kannan S
ACS Appl Mater Interfaces; 2016 Jan; 8(3):2262-79. PubMed ID: 26771508
[TBL] [Abstract][Full Text] [Related]
31. Characterization of and the influence of calcium channel blockers on the renal excretion of pyrimidine anticancer agents.
Enigbokan MA; Preston J; Hubbard C; Thompson JO
Res Commun Chem Pathol Pharmacol; 1994 Mar; 83(3):270-8. PubMed ID: 8008976
[TBL] [Abstract][Full Text] [Related]
32. Functional interaction between fluorodeoxyuridine-induced cellular alterations and replication of a ribonucleotide reductase-negative herpes simplex virus.
Petrowsky H; Roberts GD; Kooby DA; Burt BM; Bennett JJ; Delman KA; Stanziale SF; Delohery TM; Tong WP; Federoff HJ; Fong Y
J Virol; 2001 Aug; 75(15):7050-8. PubMed ID: 11435585
[TBL] [Abstract][Full Text] [Related]
33. Oncolytic reovirus combined with trastuzumab enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric cancer cells.
Hamano S; Mori Y; Aoyama M; Kataoka H; Tanaka M; Ebi M; Kubota E; Mizoshita T; Tanida S; Johnston RN; Asai K; Joh T
Cancer Lett; 2015 Jan; 356(2 Pt B):846-54. PubMed ID: 25444894
[TBL] [Abstract][Full Text] [Related]
34. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer.
Heskamp S; Laverman P; Rosik D; Boschetti F; van der Graaf WT; Oyen WJ; van Laarhoven HW; Tolmachev V; Boerman OC
J Nucl Med; 2012 Jan; 53(1):146-53. PubMed ID: 22173842
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy for gastric cancer by finely tailoring anti-Her2 anchored dual targeting immunomicelles.
Li W; Zhao H; Qian W; Li H; Zhang L; Ye Z; Zhang G; Xia M; Li J; Gao J; Li B; Kou G; Dai J; Wang H; Guo Y
Biomaterials; 2012 Jul; 33(21):5349-62. PubMed ID: 22542611
[TBL] [Abstract][Full Text] [Related]
36. Development of recombinant biomimetic nano-carrier for targeted gene transfer to HER3 positive breast cancer.
Nazari M; Minai-Tehrani A; Mousavi S; Zamani Koukhaloo S; Emamzadeh R
Int J Biol Macromol; 2021 Oct; 189():948-955. PubMed ID: 34455002
[TBL] [Abstract][Full Text] [Related]
37. Amphiphilic polymer-mediated formation of laponite-based nanohybrids with robust stability and pH sensitivity for anticancer drug delivery.
Wang G; Maciel D; Wu Y; Rodrigues J; Shi X; Yuan Y; Liu C; Tomás H; Li Y
ACS Appl Mater Interfaces; 2014 Oct; 6(19):16687-95. PubMed ID: 25167168
[TBL] [Abstract][Full Text] [Related]
38. Important role of the dihydrouracil/uracil ratio in marked interpatient variations of fluoropyrimidine pharmacokinetics and pharmacodynamics.
Jiang H; Lu J; Jiang J; Hu P
J Clin Pharmacol; 2004 Nov; 44(11):1260-72. PubMed ID: 15496644
[TBL] [Abstract][Full Text] [Related]
39. Strategy for Avoiding Protein Corona Inhibition of Targeted Drug Delivery by Linking Recombinant Affibody Scaffold to Magnetosomes.
Ma S; Gu C; Xu J; He J; Li S; Zheng H; Pang B; Wen Y; Fang Q; Liu W; Tian J
Int J Nanomedicine; 2022; 17():665-680. PubMed ID: 35185331
[TBL] [Abstract][Full Text] [Related]
40. Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.
Nam HJ; Im SA; Oh DY; Elvin P; Kim HP; Yoon YK; Min A; Song SH; Han SW; Kim TY; Bang YJ
Mol Cancer Ther; 2013 Jan; 12(1):16-26. PubMed ID: 23144237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
